340B Drug Discount Program

Report Slams 340B Drug Discount ProgramA Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.
The Winners and Losers of 340B Changes
The Winners and Losers of 340B ChangesWhat CMS' big changes to the 340B Drug Discount Program will mean.
New 340B drug rule sets drugmaker finesConsumer health groups are praising Health and Human Services’ (HHS) new rule on the Medicaid 340B drug discount program, which sets a ceiling on drug prices.
Top 10 Managed Healthcare Executive articles of 2015What Managed Healthcare Executive content was most popular this year? Find out here.
340B hospitals cost Medicare more than 50% more for cancer careA recent report evaluates the "true cost" of the 340B program. Read the key findings.
Fighting back against 340B criticismsIn this commentary, three pharmacy experts explain why they believe the 340B Drug Program is a needed safety net for safety net hospitals.
Hospitals ask Congress to protect 340B pricing programMore than 500 CEOs of hospitals and health systems urged Congress to protect the 340B drug pricing program, which helps fund free and low-cost medication access and clinics for the underserved.
340B drug program causing controversyControversy surrounds the 340B Drug Discount Program, and many industry leaders agree that the healthcare law plays a large part.